Matthew D Breyer

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 4

Top Topics

Diabetic Nephropathy

Tyrosine Kinase

Top Venues

Clinical journal of the American Society of Nephrology : CJASN

The Journal of experimental medicine

Janssen Research and Development Spring House

University of Michigan (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Janssen Research and Development Spring House Apr 05 2018

United States

Distinguished Scientist :: Cardiovascular and Metabolism

Eli Lilly and Company Jan 01 2007 - Dec 31 2017

United States

Chief Scientific Officer, Lead Generation :: Biotechnology Discovery research

Vanderbilt University Nov 01 1985 - Dec 31 2006

United States

Professor of Medicine, Nephrology :: Medicine

Education History

University of Michigan Sep 01 1971 - May 06 1979

United States

BSC

Publications

Matthew D Breyer
AKR1A1 and Kidney Disease: Promise and Perils of the Multiverse. Diabetes 73 (7) (2024)
Matthew D Breyer
AKR1A1 and Kidney Disease: Promise and Perils of the Multiverse. Diabetes 73 (7) (2024)
Dermot F Reilly, Matthew D Breyer
The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. Clinical journal of the American Society of Nephrology : CJASN 15 (9) (2020)
Isabel A Carota, Yael Kenig-Kozlovsky, Tuncer Onay, Rizaldy P Scott, Benjamin R Thomson, Tomokazu Souma, Christina S Bartlett, Yanyang Li, Daniele Procissi, Veronica Ramirez, Shinji Yamaguchi, Antoine Tarjus, Christine E Tanna, Chengjin Li, Vera Eremina, Dietmar Vestweber, Sunday S Oladipupo, Matthew D Breyer, Susan E Quaggin
Targeting VE-PTP phosphatase protects the kidney from diabetic injury. The Journal of experimental medicine 216 (4) (2019)